Cleveland Clinic 2nd Annual Cleveland Clinic Cancer Conference 2026

Multidisciplinary Oncology Updates in Precision Medicine, Immunotherapy, Hematologic Malignancies & Solid Tumors

Cancer care continues evolving at extraordinary speed as advances in genomics, immunotherapy, molecular diagnostics, cellular therapy, and precision oncology reshape how clinicians diagnose and treat malignancies across every stage of disease. The Cleveland Clinic 2nd Annual Cancer Conference 2026 delivers a broad, multidisciplinary review of contemporary oncology practice through expert-led discussions covering hematologic malignancies, solid tumors, targeted therapies, palliative medicine, artificial intelligence, and emerging cancer technologies.

Built around the theme “Innovations in Multidisciplinary Care,” this conference brings together specialists from medical oncology, hematology, radiation oncology, surgical oncology, precision medicine, and supportive care to examine how modern cancer management increasingly depends on integrated, personalized treatment strategies.

This educational package includes:

• 37 Video Lectures
• 1 PDF File
• Total Size: 5.02 GB
• Release Date: March 2, 2026

Held at the Margaritaville Hollywood Beach Resort in Florida and simultaneously streamed online, the conference reflects the growing complexity of modern oncology, where treatment decisions increasingly require collaboration across multiple specialties and evolving molecular technologies.

The Shift Toward Precision Oncology

One of the central themes throughout the conference is the continued transition from traditional organ-based cancer treatment toward precision-driven oncology.

Modern oncology increasingly incorporates:

• Genomic profiling
• Minimal residual disease (MRD) monitoring
• Molecular biomarkers
• Targeted therapies
• Cellular immunotherapy
• AI-assisted clinical decision-making

The course repeatedly emphasizes that many cancers once managed uniformly are now stratified according to:

• Molecular signatures
• Driver mutations
• Tumor microenvironment characteristics
• Immune responsiveness
• Treatment resistance pathways

This shift has fundamentally changed both prognosis assessment and therapeutic sequencing.

Hematologic Malignancies & Cellular Therapy

The hematologic oncology sessions provide updates on:

• Myeloproliferative neoplasms
• Myelodysplastic syndromes (MDS)
• Acute myeloid leukemia (AML)
• Multiple myeloma
• AL amyloidosis
• CAR-T cell therapy

The discussions examine how advances in molecular genetics and immune-based therapies are rapidly transforming hematologic cancer management.

One recurring challenge in hematologic oncology involves balancing:

• Disease control
• Treatment toxicity
• Transplant eligibility
• Long-term quality of life
• Relapse prevention

particularly in older or medically complex patients.

The CAR-T and cellular therapy lectures explore the expanding role of engineered immune therapies in refractory malignancies and the evolving management of treatment-related complications.

Genomics, AI & Personalized Cancer Care

The precision oncology sessions focus heavily on emerging technologies.

Topics include:

• Genetic testing strategies
• Minimal residual disease monitoring
• Artificial intelligence in oncology
• Precision oncology case discussions
• Personalized therapeutic planning

MRD monitoring has become increasingly important because it allows clinicians to detect microscopic residual disease long before radiographic relapse becomes apparent.

The AI discussions explore how machine learning may influence:

• Imaging interpretation
• Treatment prediction
• Workflow optimization
• Clinical trial matching
• Prognostic modeling

At the same time, the course appropriately acknowledges that integrating AI into oncology practice still presents important ethical, logistical, and validation challenges.

Lung Cancer: Rapidly Changing Treatment Paradigms

The lung cancer sessions review:

• Early-stage NSCLC management
• Locally advanced disease
• Metastatic NSCLC
• Small cell lung cancer
• Surgical challenges after neoadjuvant therapy

Thoracic oncology continues evolving rapidly through:

• Immunotherapy combinations
• Molecular-targeted agents
• Neoadjuvant systemic therapy
• Biomarker-driven treatment selection

Clinical decision-making becomes increasingly complex when determining:

• Surgical timing
• Adjuvant therapy
• Molecular testing priorities
• Sequencing of systemic treatment

particularly in patients with multiple targetable mutations or mixed histologic features.

Supportive Oncology & Palliative Medicine

The palliative care sessions are especially valuable because modern oncology increasingly recognizes symptom management as a core component of comprehensive cancer treatment.

Topics include:

• Cancer cachexia
• Fatigue management
• Neuropathy treatment
• Benzodiazepine use in oncology
• Integrative therapies such as acupuncture

The course appropriately emphasizes that supportive oncology is not limited to end-of-life care, but instead plays a major role throughout the cancer continuum.

In practice, many treatment-limiting complications arise not directly from cancer progression, but from:

• Nutritional decline
• Neuropathic toxicity
• Functional deterioration
• Psychological distress
• Symptom burden

Novel Therapies & Emerging Drug Platforms

The novel therapeutics section reviews several rapidly evolving treatment modalities, including:

• Antibody-drug conjugates (ADCs)
• RNA therapeutics
• Cellular therapies
• Organ-preservation strategies
• Clinical complete response (cCR) assessment

Antibody-drug conjugates have become one of the most important developments in modern oncology because they combine:

• Target specificity
• Cytotoxic delivery
• Improved therapeutic precision

The conference also explores how RNA-based therapeutics may reshape future cancer treatment through highly individualized molecular targeting approaches.

Gynecologic Oncology, Sarcoma & Melanoma

The solid tumor discussions address:

• Gynecologic cancers
• Sarcoma
• Melanoma
• Head and neck cancers
• Non-melanoma skin cancers

The sarcoma sessions are particularly relevant because sarcoma management often requires highly specialized multidisciplinary coordination involving:

• Surgical oncology
• Radiation oncology
• Molecular pathology
• Systemic therapy selection

Meanwhile, melanoma therapy continues evolving through increasingly sophisticated immunotherapy combinations and biomarker-guided approaches.

Gastrointestinal Oncology

The GI oncology sessions review:

• Early-onset colorectal cancer
• Gastroesophageal cancers
• Colorectal liver metastases
• Surgical innovation
• Shifting systemic therapy paradigms

Early-onset GI cancers have become an especially important area of investigation as incidence rises in younger populations without traditional risk profiles.

The lectures explore:

• Genetic predisposition
• Screening implications
• Molecular differences
• Evolving therapeutic strategies

Breast Cancer Updates

The breast oncology section examines:

• Breast surgery advances
• Radiation oncology updates
• Adjuvant systemic therapy
• Metastatic breast cancer treatment
• ADCs in advanced disease

Breast oncology remains one of the fastest-changing areas in cancer medicine due to rapid integration of:

• Targeted therapies
• HER2-directed treatment evolution
• Precision endocrine strategies
• Molecular profiling

Multidisciplinary Tumor Board Learning

A major strength of the conference is its extensive use of tumor board case discussions.

These sessions simulate real-world oncology decision-making where management often depends on integrating:

• Imaging findings
• Pathology interpretation
• Genomic data
• Surgical feasibility
• Radiation planning
• Systemic therapy options

The tumor board format highlights the reality that modern oncology care is increasingly collaborative rather than specialty-isolated.

Real-World Clinical Relevance

The conference repeatedly emphasizes:

• Evidence-based treatment integration
• Translating clinical trial data into practice
• Emerging technology adoption
• Personalized treatment planning
• Supportive care optimization

Importantly, the course avoids focusing solely on theoretical advances and instead addresses how clinicians apply rapidly changing oncology data in everyday patient management.

What’s Included

• 37 oncology video lectures
• 1 PDF file
• Total size: 5.02 GB
• Precision oncology and genomics discussions
• Hematologic malignancy updates
• Lung, breast, GI, gynecologic, and skin cancer sessions
• CAR-T and novel therapy reviews
• Multidisciplinary tumor board case discussions

Final Expert Perspective

Modern oncology is increasingly defined by precision medicine, multidisciplinary collaboration, and rapidly evolving therapeutic technologies. Molecular diagnostics, cellular therapies, immunotherapy combinations, and AI-assisted clinical tools are reshaping how clinicians approach both common and highly complex malignancies.

The Cleveland Clinic 2nd Annual Cancer Conference 2026 provides a broad and clinically relevant review of these developments through expert-led discussions spanning hematologic malignancies, solid tumors, supportive oncology, precision medicine, and emerging therapeutic strategies. For oncologists, hematologists, radiation specialists, and multidisciplinary cancer care professionals, this conference offers a valuable overview of contemporary oncology practice and future treatment directions.

Topics:

Session 1 – Updates and State of the Art Therapy in Hematologic Malignancies
Advances in the Management of Myeloproliferative Neoplasm	Yehuda Galili, MD
Recent Advances in MDS and AML: What’s Practice Changing?	Akriti Jain, MD
Advances in the Management of Myeloma/AL Amyloidosis	Jack Khouri, MD
Tumor Boards Case Panels	Betty Hamilton, MD; Alex Mejia Garcia, MD
Session 2 – Genomics/Precision Oncology
Genetic Testing: What Oncologists Should Know	Sara Rhode, MS, CGC
The Future of AI in Cancer Care	Ali Zarrinpar, MD, PhD
The Power of Minimal Residual Disease Monitoring in Personalized Cancer Care	Shlomo Koyfman, MD
Precision Oncology Case Presentation and Panel Discussion	Jacob Miller, MD
Session 3 – Updates and State of the Art Therapy in Lung Cancer
Surgical Challenges After Neo-Adjuvant Therapy	Monisha Sudarshan, MD, MPH
Treatment of Early-Stage and Locally Advanced NSCLC	Suresh S. Ramalingam, MD
Special Issues in Managing Metastatic NSCLC	Khaled Hassan, MD
Current Management of Small Cell Lung Cancer	Lukas Delasos, DO
Tumor Boards Case Panels	Khaled Hassan, MD; Diana Saravia, MD
Session 4 – Key Issues in Palliative Care
Cancer Related Anorexia-Cachexia Syndrome and Cancer Related Fatigue: Evidence Based Management and Emerging Treatments	Nivia Ruiz, MD
Acupuncture’s Role in Cancer-Related Symptom Management	Thuy Nguyen, DAOM, LAc
Benzodiazepines: Friend or Foe?	Kaleena Chilcote, MD
Cancer Therapy-Induced Neuropathy Management	Renato Samala, MD
Tumor Boards Case Panels	Laura Shoemaker, DO
Session 5 – Novel Therapies
Antibody Drug Conjugate: Innocent Bystander?	Wen Wee Ma, MBBS
CAR-T Cells and Cellular Therapy	Paolo Caimi, MD
Innovations in Anti-Cancer RNA Therapeutics	Natalie Silver, MD
When to Watch and Wait vs. Refer to Surgery: Best Practices for Defining cCR After TNT	Emre Gorgun, MD
Tumor Boards Case Panels	Wen Wee Ma, MBBS; Natalie Silver, MD
Session 6 – Updates and State of the Art Therapy in Selected Solid Tumors
Multidisciplinary Management of Gynecologic Cancers	Robert DeBernardo, MD
Advancing Sarcoma Therapy: Integrating Immunotherapy, Cellular Strategies and Targeted Payloads	Dale Shepard, MD, PhD
Melanoma	James Isaacs, MD
State of the Art Therapy in Head/Neck and Non-Melanoma Skin Cancers: Updates in Particle Therapy and Perioperative Immunotherapy	Jacob Miller, MD
Tumor Boards Case Panels	Robert DeBernardo, MD; Sudha Amarnath, MD
Session 7 – Updates and State of the Art Therapy in GI Cancers
Early-Onset Colorectal and Other GI Cancers: Implications for Diagnosis and Treatment	Alok Khorana, MD
Novel Surgical Strategies in Colorectal Liver Metastases	Federico Aucejo, MD
Shifting Treatment Paradigms in Gastro-Esophageal Cancers	Suneel Kamath, MD
Tumor Boards Case Panels	Matthew Walsh, MD; Alok Khorana, MD
Session 8 – Breast Cancer
Breast Surgery Update	Stephen Grobmyer, MD
Breast Radiation Oncology Updates	Praveen Pendyala, MD
Advances in Adjuvant Therapy for Breast Cancer	Erin Roesch, MD
Latest Updates on the Management of Metastatic Breast Cancer: Antibody -Drug Conjugates for Advanced Stage Disease	Rita Nanda, MD
Tumor Boards Case Panels	Megan Kruse, MD; Stephen Grobmyer, MD